EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

From Prognostic Determinants to Trajectory-Based Risk Stratification in Pediatric Dilated Cardiomyopathy: Clinical Implications for Therapeutic Decision-Making — A Narrative Review

Rafif Ali, Samir Srour

F1000Research · 01.06.2026 · 15 · 843

DOI: 10.12688/f1000research.179016.1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift F1000Research, online erschienen am 01.06.2026. Verfasst von Rafif Ali und 1 weiteren Autor:innen. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pediatric dilated cardiomyopathy (DCM) is one of the rare causes of heart failure in children that can be fatal without early diagnosis and treatment. The dis-ease has highly variable outcomes: some patients may require HTx, some may die early without timely treatment, whereas a smaller subset of children may recover partially. This narrative review integrates up-to-date prognostic evidence from clini-cal presentation, echocardiography and advanced imaging, circulating biomarkers, and genetic findings, while also recognizing that resource context and access to ad-vanced therapies may influence the endpoints observed. In all cohorts and imaging syntheses, three echocardiographic features are the main factors that consistently determine the risk: left ventricular systolic dysfunction, pronounced left ventricu-lar dilation (LVEDD z-score), and intensive functional mitral regurgitation. Prog-nosis changes over time; early trajectories, improvement vs. persistence or pro-gression of dysfunction and dilation, often provide greater refinement of risk than baseline severity. Out of various laboratory measurements, natriuretic peptides (NT-proBNP/BNP) remain the most widely confirmed prognostic biomarkers, especially if they are measured serially as quantifiable markers of hemodynamic stress and treatment response. Inflammatory indices derived from CBC (e.g., NLR/SII) along with routine chemistry abnormalities might offer additional low-cost information but need to be validated in larger, multicenter studies. Genomic testing is progressively unveiling previously”idiopathic” diseases and has the potential to alter risk, notably in arrhythmia- or conduction-prone genotypes, hence it advocates detection and family screening on the basis of the genotype. Integrating these areas, we identify a multi-layered, down-to-earth approach for risk assessment at diagnosis, with regular updating during early follow-up through serial imaging and biomarkers, thus allowing for timely escalation of treatment in high-risk children and personalized monitoring for those who show reverse remodeling.

Zitieren

APA

Ali, R., & Srour, S. (2026). From Prognostic Determinants to Trajectory-Based Risk Stratification in Pediatric Dilated Cardiomyopathy: Clinical Implications for Therapeutic Decision-Making — A Narrative Review. F1000Research, 15, 843. https://doi.org/10.12688/f1000research.179016.1

Vancouver

Ali R, Srour S. From Prognostic Determinants to Trajectory-Based Risk Stratification in Pediatric Dilated Cardiomyopathy: Clinical Implications for Therapeutic Decision-Making — A Narrative Review. F1000Research. 2026;15:843. doi:10.12688/f1000research.179016.1

BibTeX
@article{Ali2026,
  author = {Ali, Rafif and Srour, Samir},
  title = {From Prognostic Determinants to Trajectory-Based Risk Stratification in Pediatric Dilated Cardiomyopathy: Clinical Implications for Therapeutic Decision-Making — A Narrative Review},
  journal = {F1000Research},
  year = {2026},
  volume = {15},
  pages = {843},
  doi = {10.12688/f1000research.179016.1}
}
Kostenlos starten →